The stock of Bionano Genomics Inc (BNGO) has gone down by -19.50% for the week, with a -36.31% drop in the past month and a -36.31% drop in the past quarter. The volatility ratio for the week is 8.46%, and the volatility levels for the past 30 days are 7.05% for BNGO. The simple moving average for the past 20 days is -25.38% for BNGO’s stock, with a -55.36% simple moving average for the past 200 days.
Is It Worth Investing in Bionano Genomics Inc (NASDAQ: BNGO) Right Now?
The 36-month beta value for BNGO is at 2.42. Analysts have varying views on the stock, with 2 analysts rating it as a “buy,” 0 rating it as “overweight,” 0 as “hold,” and 0 as “sell.”
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The public float for BNGO is 68.45M, and currently, shorts hold a 6.85% of that float. The average trading volume for BNGO on June 25, 2024 was 1.31M shares.
BNGO) stock’s latest price update
Bionano Genomics Inc (NASDAQ: BNGO)’s stock price has gone decline by -5.52 in comparison to its previous close of 0.69, however, the company has experienced a -19.50% decrease in its stock price over the last five trading days. globenewswire.com reported 2024-06-20 that Bionano has entered into a software marketing agreement with Revvity, Inc. (Revvity) under which Revvity will market and commercialize Bionano’s VIA™ software to Revvity’s next generation sequencing (NGS) customers as part of its newborn sequencing research workflow VIA is expected to enhance Revvity’s newborn sequencing solution by adding an assessment of copy number variation (CNV) to the NGS solution report and streamlining the workflow’s interpretation capabilities SAN DIEGO, June 20, 2024 (GLOBE NEWSWIRE) — Bionano Genomics, Inc. (Nasdaq: BNGO), today announced that it has entered into a software marketing agreement with Revvity, Inc. (NYSE: RVTY) under which Revvity will market and commercialize Bionano’s VIA™ software as part their newborn sequencing research workflow. VIA is expected to enhance the comprehensive reporting capabilities of Revvity’s sequencing solution by adding an assessment of CNVs to its NGS workflow and streamlining the workflow’s interpretation capabilities.
Analysts’ Opinion of BNGO
Many brokerage firms have already submitted their reports for BNGO stocks, with Scotiabank repeating the rating for BNGO by listing it as a “Sector Outperform.” The predicted price for BNGO in the upcoming period, according to Scotiabank is $4 based on the research report published on January 05, 2023 of the previous year 2023.
BTIG Research, on the other hand, stated in their research note that they expect to see BNGO reach a price target of $3.50. The rating they have provided for BNGO stocks is “Buy” according to the report published on December 12th, 2022.
Oppenheimer gave a rating of “Outperform” to BNGO, setting the target price at $12 in the report published on July 18th of the previous year.
BNGO Trading at -28.27% from the 50-Day Moving Average
After a stumble in the market that brought BNGO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -90.29% of loss for the given period.
Volatility was left at 7.05%, however, over the last 30 days, the volatility rate increased by 8.46%, as shares sank -38.83% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -33.04% lower at present.
During the last 5 trading sessions, BNGO fell by -19.68%, which changed the moving average for the period of 200-days by -80.55% in comparison to the 20-day moving average, which settled at $0.8583. In addition, Bionano Genomics Inc saw -65.29% in overturn over a single year, with a tendency to cut further losses.
Stock Fundamentals for BNGO
Current profitability levels for the company are sitting at:
- -5.33 for the present operating margin
- 0.28 for the gross margin
The net margin for Bionano Genomics Inc stands at -6.05. The total capital return value is set at -2.01. Equity return is now at value -144.33, with -100.76 for asset returns.
Based on Bionano Genomics Inc (BNGO), the company’s capital structure generated 0.34 points at debt to capital in total, while cash flow to debt ratio is standing at -2.92. The debt to equity ratio resting at 0.52. The interest coverage ratio of the stock is -38.65.
Currently, EBITDA for the company is -125.72 million with net debt to EBITDA at -0.25. When we switch over and look at the enterprise to sales, we see a ratio of 1.95. The receivables turnover for the company is 4.4for trailing twelve months and the total asset turnover is 0.24. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.46.
Conclusion
In conclusion, Bionano Genomics Inc (BNGO) has had a bad performance lately. Opinion on the stock among analysts is bullish, with some giving it a “buy” rating and others a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
